The founder and CEO of Seattle Genetics, Clay Siegall has been making an impact in business for quite some time. His company Seattle Genetics specializes in the development of drugs for diseases that have not seen improvement in their treatment in years. Siegall recently sat down with Inspirery to share some insight into his success and how what drives him each day.
When asked what got him started in business, Siegall has an intriguing answer. He has always had an interest in medicine and technology. He has always been curious on how to restore health to major diseases. While studying at the University of Maryland he specifically became interested in cancer research. A personal situation where a family member nearly died from cancer treatment really got Siegall’s attention. He soon began researching other treatment methods. Siegall is honest however when he says that money is also a huge factor in why he got into business.
Siegall makes money because his company Seattle Genetics sells their own proprietary drugs. He makes a lot of money off the drug ADCetris. Despite the success, it took Siegall’s company nearly a decade to become profitable. To gain the business of companies Siegall spends lots of time wining and dining his clients to negotiate a deal. Getting the 7 to 8 figure deals are not simple, but Siegall credits his hard work as the key to his success.
Founder of Seattle Genetics, Clay Siegall has put in years of work to attain his success. He has two degrees holding a a B.S. in zoology from The University of Maryland and also a Ph.D in genetics from George Washington University. Dr. Siegall is responsible for creating the first FDA-approved antibody drug conjugate which now has multiple indications. His company is making major changes to the medical world and
well positioned to continue to make change in the future.
Dr. Siegall’s work is responsible for more than securing more than $675 million in public and private financing. Outside of Seattle Genetics he has worked with a number of successful groups including Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and the National Institutes of Health. He also is an accomplished author with more than 70 publications.